Right to Try Laws: Can States Unlock Longevity Therapies?
Montana has passed a law that could let you access certain longevity-focused therapies — including drugs like rapamycin — without waiting for the FDA to formally approve them for that purpose.
Montana has passed a law that could let you access certain longevity-focused therapies — including drugs like rapamycin — without waiting for the FDA to formally approve them for that purpose. That is a genuinely significant development, but the details matter enormously, and the gap between what the law says and what it can actually deliver is wider than most headlines suggest. Right to Try laws have existed at the federal level since 2018, originally designed to help terminally ill patients access experimental treatments. Montana's newer version stretches that concept into preventative medicine, which is new legal territory. If you have been following longevity researchers like Matt Kaeberlein or tracking the broader conversation about proactive aging, this is the story worth understanding carefully. Vitals Vault's PocketMD team and lab panels can help you build the baseline picture of your own biology before any conversation about emerging therapies.
Why this is trending
Aging researcher Matt Kaeberlein published four separate videos this week focused specifically on Montana's Right to Try law, making it one of the most concentrated topic clusters in the longevity space right now. His core argument is that the law creates a meaningful, if imperfect, pathway for healthy adults to access drugs like rapamycin for preventative purposes — something the current FDA framework does not easily allow because aging itself is not classified as a disease. The broader tension here is real and not new: the FDA regulates drugs based on specific disease indications, which means a drug that might slow biological aging has no clear approval pathway even if the science is compelling. States are now testing whether they can work around that constraint, and Montana is the most concrete example so far. Whether that experiment holds up legally and practically is still an open question.
What Montana's Right to Try Law Actually Is
A state law expanding access beyond terminal illness
Traditional Right to Try laws, including the 2018 federal version, were written for people with life-threatening conditions who had exhausted approved options. Montana's law extends that logic to preventative therapies, meaning a healthy person who wants to reduce their risk of age-related disease could potentially qualify — which is a significant philosophical and legal shift.
It works through licensed physicians, not around them
The law does not let you order experimental drugs online or bypass a doctor. A licensed Montana physician must be willing to prescribe the therapy, and they take on real professional and legal responsibility by doing so. That means the practical availability of these therapies depends heavily on how many doctors are actually willing to participate.
Rapamycin is the drug most discussed in this context
Rapamycin (also called sirolimus) is an FDA-approved immunosuppressant used in organ transplant patients, but researchers have been studying it for years as a potential longevity drug because of how it interacts with a cellular aging pathway called mTOR. Using it in healthy people for longevity purposes is off-label, and Montana's law is one of the first attempts to create a formal state-level framework for exactly that kind of use.
Lab testing
Before exploring any longevity intervention, know your baseline. Our starting-from-$99 panel covers 100+ tests in one visit — including metabolic markers, inflammation, and hormones that matter most for healthy aging.
Schedule online, results in a week
Clear guidance, follow-up care available
HSA/FSA Eligible
Why This Is Getting So Much Attention Right Now
The FDA does not recognize aging as a disease
This is the core regulatory problem that Montana's law is trying to solve. Because the FDA approves drugs for specific diseases rather than for aging itself, there is no straightforward path for a drug company to run trials and get approval for a longevity indication — which means promising compounds stay in a gray zone indefinitely. States stepping in to fill that gap is a direct response to that structural limitation.
Longevity researchers are publicly endorsing the concept
When credible scientists like Kaeberlein — who has spent years studying rapamycin in animal models — start making videos specifically about a state law, it signals that the research community sees this as more than a political stunt. That kind of endorsement moves the conversation from fringe biohacking forums into mainstream health discussions, which is part of why it is landing in your feed right now.
Wealthy longevity clinics already exist, and this could democratize access
Right now, access to off-label longevity therapies is largely a function of money and geography — you need to find the right concierge clinic and pay out of pocket. A state law that creates a clearer legal framework could, in theory, make it easier for more physicians to participate without fear of professional repercussions, which would broaden access beyond the current wealthy-early-adopter demographic.
What the Science Actually Shows
Animal data on rapamycin is genuinely impressive
In multiple mouse studies, rapamycin extended lifespan by 10 to 25 percent even when started late in life, which is unusual for any intervention. The mechanism involves inhibiting a protein complex called mTOR (mechanistic target of rapamycin) that acts like a cellular growth throttle — dialing it back appears to trigger repair processes that normally slow down with age.
Human longevity data is still preliminary
There are no completed randomized controlled trials showing that rapamycin extends healthy lifespan in humans. What exists are smaller studies suggesting it may improve immune function in older adults and some observational data from people who have been taking it off-label for years. That is genuinely promising, but it is not the same as proven, and anyone telling you otherwise is overstating the evidence.
The Dog Aging Project offers the most rigorous ongoing data
Kaeberlein has been a lead researcher on the Dog Aging Project, which is studying rapamycin in pet dogs as a model for human aging. Early results have been encouraging for cardiac function, but the full longevity results are not yet published. Dogs are a better biological proxy for humans than mice, so this data is watched closely by the research community.
Other longevity compounds are also in this conversation
Rapamycin gets the most attention, but Montana's law could in principle apply to other compounds being studied for aging — including metformin, which is already FDA-approved for diabetes and is being tested in the TAME trial for longevity effects. The law's framework matters beyond any single drug, because it sets a precedent for how states might handle future longevity interventions.
How the Law Actually Works in Practice
You need to be in Montana — or willing to go there
The law applies to Montana-licensed physicians practicing in Montana, which means you cannot simply call a Montana doctor from another state and get a prescription mailed to you. Whether medical tourism to Montana for longevity consultations becomes a real phenomenon is something the next year or two will reveal.
The physician-patient relationship carries the legal weight
Under the law, the prescribing physician must document that you understand the therapy is not FDA-approved for this purpose and that you are consenting to that uncertainty. That informed consent process is not a formality — it is the legal mechanism that gives the physician some protection and ensures you are making a genuinely informed choice rather than just signing a waiver.
Federal law still applies, and the tension is unresolved
Here is the part that does not get enough attention: the FDA operates under federal law, which supersedes state law. Montana can say its physicians are protected under state law, but the federal government has not agreed to stand down, and no court has yet tested whether this kind of state preventative Right to Try law survives a federal challenge. That legal uncertainty is real and should factor into any decision you make.
What You Should Know Before Getting Excited
Rapamycin has real side effects that matter
Because rapamycin suppresses part of the immune system, it can increase susceptibility to certain infections and slow wound healing. At the lower intermittent doses being discussed for longevity purposes, these risks appear smaller than in transplant patients who take it daily at higher doses — but they are not zero, and anyone with an autoimmune condition, active infection, or certain metabolic issues needs a careful medical evaluation before considering it.
The legal framework is genuinely untested
No one has yet been prosecuted or had their license challenged under Montana's law, which means we do not actually know how federal regulators will respond if they choose to push back. Physicians participating in good faith are taking on real professional risk, and that uncertainty is one reason the pool of willing prescribers may stay small for now.
This is not a substitute for knowing your baseline health
Longevity interventions of any kind make the most sense when you already understand your metabolic health, inflammation levels, kidney function, and other markers that affect both your risk profile and how you would respond to a drug like rapamycin. Jumping into an experimental therapy without that foundation is not proactive health — it is just a different kind of guessing.
Frequently Asked Questions
Is Montana's Right to Try law legal under federal law?
That question has not been settled in court. Montana's law protects physicians under state law, but the FDA operates under federal authority, which generally takes precedence. The honest answer is that the legal durability of this law is unknown until it faces a federal challenge, which has not happened yet.
Can I get rapamycin for longevity purposes without going to Montana?
Yes, in a limited way — some physicians in other states already prescribe rapamycin off-label for longevity purposes, and that practice is not illegal. What Montana's law attempts to do is create a more explicit legal framework that gives physicians clearer protection, which could make more doctors willing to participate. Off-label prescribing itself is already legal everywhere.
What dose of rapamycin are longevity researchers talking about?
Most researchers discussing rapamycin for longevity are focused on low intermittent doses — typically once weekly rather than the daily higher doses used in transplant medicine — based on the hypothesis that this preserves benefits while reducing immune suppression risks. However, no optimal dose for longevity in humans has been established, and this is an area where you need an individualized conversation with a physician who knows your full health picture.
Does this law apply to other longevity drugs besides rapamycin?
In principle, yes — Montana's law is not limited to rapamycin specifically. It applies to therapies a physician believes have preventative longevity potential, which could include compounds like metformin or others being studied in aging research. In practice, rapamycin is the drug with the most supporting animal data and the most active physician interest right now.
How do I know if I'm a good candidate for a longevity therapy like rapamycin?
That determination requires a thorough look at your current health — kidney function, immune status, metabolic markers, and any conditions that could interact with an immunosuppressive drug. Getting a comprehensive lab panel is a sensible first step before any conversation with a physician about these therapies, because it gives both of you real data to work from rather than assumptions.